{
    "info": {
        "nct_id": "NCT04953780",
        "official_title": "2157GCCC: a Phase I Trial of Calaspargase Pegol-mknl in Combination with High Dose Cytarabine and Idarubicin in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia",
        "inclusion_criteria": "* A histologically or pathologically confirmed diagnosis of AML based on WHO classification. Patients with myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN) evolving into AML who are candidates for AML induction therapy are eligible for enrollment.\n* Age 18-65 years old.\n* ECOG performance status < 3.\n* Patients must have normal organ function as defined below:\n\n  * Total bilirubin ≤2X the institutional upper limit of normal (ULN) (except in patients with leukemic infiltration of the liver)\n  * AST(SGOT)/ALT(SGPT) ≤3X ULN (except if attributable to leukemic infiltration of the liver)\n  * Creatinine Clearance (CrCl) ≥ 40 mL/min (except in patients with evidence of tumor lysis syndrome)\n  * Left ventricular ejection fraction (LVEF) ≥50%\n* Female patients of childbearing potential must have a negative pregnancy test <1 week before enrollment. Female patients of childbearing potential who are sexually active and male patients who are sexually active and have female partners of childbearing potential must agree to use a highly effective method of non-hormonal contraception. Contraception should be used during treatment and for at least 3 months after the last dose of Calaspargase pegol-mknl.\n* Ability to understand and willingness to sign a written informed consent document.\n* Agree to comply with the study requirements and agrees to come to the clinic/hospital for required study visits\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
        "exclusion_criteria": "* Patients with the following clinical histories are excluded:\n\n  * severe pancreatitis not related to cholelithiasis. Severe acute pancreatitis as defined by lipase elevation >5X ULN and with signs or symptoms\n  * unprovoked DVT\n  * PE\n  * serious or life-threatening thrombosis in any location of the body\n  * hemorrhagic or thromboembolic stroke\n  * major hemorrhagic event within three weeks before signing ICF; hemorrhage due to thrombocytopenia from underlying AML is excluded\n  * patients with hemorrhagic diathesis\n  * neurologic/cerebellar disorders that may confound the toxicity monitoring of HiDAC\n  * history of serious hypersensitivity reactions to pegylated L-asparaginase therapy\n* Patients receiving any other investigational agents or concurrent chemotherapy or immunotherapy. Hydroxyurea for blast count control is permitted before starting treatment and up to a maximum of 10 days after starting treatment on the study.\n* Patients with AML with any of the following cytogenetic abnormalities: t(15;17), t(8;21), inv(16), t(16;16).\n* Pregnant women and female patients who are lactating and do not agree to stop breast-feeding.\n* Uncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled active seizure disorder, or psychiatric illness/social situations that per site Principal Investigator's judgment would limit compliance with study requirements",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have maximum age of 65 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 65 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 65,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age 18-65 years old.",
            "criterions": [
                {
                    "exact_snippets": "Age 18-65 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 65,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status < 3.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status < 3",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have normal organ function as defined below:",
            "criterions": [
                {
                    "exact_snippets": "Patients must have normal organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to understand and willingness to sign a written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine Clearance (CrCl) ≥ 40 mL/min (except in patients with evidence of tumor lysis syndrome)",
            "criterions": [
                {
                    "exact_snippets": "Creatinine Clearance (CrCl) ≥ 40 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except in patients with evidence of tumor lysis syndrome",
                    "criterion": "tumor lysis syndrome",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) ≥50%",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) ≥50%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST(SGOT)/ALT(SGPT) ≤3X ULN (except if attributable to leukemic infiltration of the liver)",
            "criterions": [
                {
                    "exact_snippets": "AST(SGOT)/ALT(SGPT) ≤3X ULN",
                    "criterion": "AST (SGOT) and ALT (SGPT) levels",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except if attributable to leukemic infiltration of the liver",
                    "criterion": "leukemic infiltration of the liver",
                    "requirements": [
                        {
                            "requirement_type": "attribution",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin ≤2X the institutional upper limit of normal (ULN) (except in patients with leukemic infiltration of the liver)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤2X the institutional upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except in patients with leukemic infiltration of the liver",
                    "criterion": "leukemic infiltration of the liver",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A histologically or pathologically confirmed diagnosis of AML based on WHO classification. Patients with myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN) evolving into AML who are candidates for AML induction therapy are eligible for enrollment.",
            "criterions": [
                {
                    "exact_snippets": "histologically or pathologically confirmed diagnosis of AML based on WHO classification",
                    "criterion": "acute myeloid leukemia (AML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "pathological"
                            ]
                        },
                        {
                            "requirement_type": "classification system",
                            "expected_value": "WHO"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN) evolving into AML who are candidates for AML induction therapy",
                    "criterion": "MDS or MPN evolving into AML",
                    "requirements": [
                        {
                            "requirement_type": "disease evolution",
                            "expected_value": "MDS or MPN evolving into AML"
                        },
                        {
                            "requirement_type": "candidate for AML induction therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agree to comply with the study requirements and agrees to come to the clinic/hospital for required study visits",
            "criterions": [
                {
                    "exact_snippets": "Agree to comply with the study requirements",
                    "criterion": "compliance with study requirements",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agrees to come to the clinic/hospital for required study visits",
                    "criterion": "attendance at required study visits",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients of childbearing potential must have a negative pregnancy test <1 week before enrollment. Female patients of childbearing potential who are sexually active and male patients who are sexually active and have female partners of childbearing potential must agree to use a highly effective method of non-hormonal contraception. Contraception should be used during treatment and for at least 3 months after the last dose of Calaspargase pegol-mknl.",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential must have a negative pregnancy test <1 week before enrollment",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "test timing",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "week before enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Female patients of childbearing potential who are sexually active and male patients who are sexually active and have female partners of childbearing potential must agree to use a highly effective method of non-hormonal contraception. Contraception should be used during treatment and for at least 3 months after the last dose of Calaspargase pegol-mknl.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "highly effective method of non-hormonal contraception"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "during treatment",
                                "at least 3 months after the last dose of Calaspargase pegol-mknl"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* PE",
            "criterions": [
                {
                    "exact_snippets": "PE",
                    "criterion": "pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* unprovoked DVT",
            "criterions": [
                {
                    "exact_snippets": "unprovoked DVT",
                    "criterion": "deep vein thrombosis (DVT)",
                    "requirements": [
                        {
                            "requirement_type": "provoked status",
                            "expected_value": "unprovoked"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with the following clinical histories are excluded:",
            "criterions": [
                {
                    "exact_snippets": "Patients with the following clinical histories are excluded",
                    "criterion": "clinical history",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* patients with hemorrhagic diathesis",
            "criterions": [
                {
                    "exact_snippets": "patients with hemorrhagic diathesis",
                    "criterion": "hemorrhagic diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* serious or life-threatening thrombosis in any location of the body",
            "criterions": [
                {
                    "exact_snippets": "serious or life-threatening thrombosis in any location of the body",
                    "criterion": "thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "serious",
                                "life-threatening"
                            ]
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "any location of the body"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* neurologic/cerebellar disorders that may confound the toxicity monitoring of HiDAC",
            "criterions": [
                {
                    "exact_snippets": "neurologic/cerebellar disorders that may confound the toxicity monitoring of HiDAC",
                    "criterion": "neurologic/cerebellar disorders",
                    "requirements": [
                        {
                            "requirement_type": "potential to confound HiDAC toxicity monitoring",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* history of serious hypersensitivity reactions to pegylated L-asparaginase therapy",
            "criterions": [
                {
                    "exact_snippets": "history of serious hypersensitivity reactions to pegylated L-asparaginase therapy",
                    "criterion": "hypersensitivity reactions to pegylated L-asparaginase therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* hemorrhagic or thromboembolic stroke",
            "criterions": [
                {
                    "exact_snippets": "hemorrhagic ... stroke",
                    "criterion": "hemorrhagic stroke",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "thromboembolic stroke",
                    "criterion": "thromboembolic stroke",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* severe pancreatitis not related to cholelithiasis. Severe acute pancreatitis as defined by lipase elevation >5X ULN and with signs or symptoms",
            "criterions": [
                {
                    "exact_snippets": "severe pancreatitis not related to cholelithiasis",
                    "criterion": "severe pancreatitis",
                    "requirements": [
                        {
                            "requirement_type": "relation to cholelithiasis",
                            "expected_value": "not related"
                        }
                    ]
                },
                {
                    "exact_snippets": "Severe acute pancreatitis as defined by lipase elevation >5X ULN",
                    "criterion": "acute pancreatitis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "lipase elevation",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Severe acute pancreatitis ... with signs or symptoms",
                    "criterion": "acute pancreatitis",
                    "requirements": [
                        {
                            "requirement_type": "signs or symptoms",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant women and female patients who are lactating and do not agree to stop breast-feeding.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "female patients who are lactating and do not agree to stop breast-feeding",
                    "criterion": "lactation and willingness to stop breast-feeding",
                    "requirements": [
                        {
                            "requirement_type": "lactation status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "willingness to stop breast-feeding",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* major hemorrhagic event within three weeks before signing ICF; hemorrhage due to thrombocytopenia from underlying AML is excluded",
            "criterions": [
                {
                    "exact_snippets": "major hemorrhagic event within three weeks before signing ICF",
                    "criterion": "major hemorrhagic event",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks before signing ICF"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hemorrhage due to thrombocytopenia from underlying AML is excluded",
                    "criterion": "hemorrhage due to thrombocytopenia from underlying AML",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with AML with any of the following cytogenetic abnormalities: t(15;17), t(8;21), inv(16), t(16;16).",
            "criterions": [
                {
                    "exact_snippets": "AML",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cytogenetic abnormalities: t(15;17), t(8;21), inv(16), t(16;16)",
                    "criterion": "cytogenetic abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "t(15;17)",
                                "t(8;21)",
                                "inv(16)",
                                "t(16;16)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled active seizure disorder, or psychiatric illness/social situations that per site Principal Investigator's judgment would limit compliance with study requirements",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled active seizure disorder",
                    "criterion": "seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that per site Principal Investigator's judgment would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations",
                    "requirements": [
                        {
                            "requirement_type": "PI judgment of compliance limitation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients receiving any other investigational agents or concurrent chemotherapy or immunotherapy. Hydroxyurea for blast count control is permitted before starting treatment and up to a maximum of 10 days after starting treatment on the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving any other investigational agents",
                    "criterion": "use of investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "concurrent chemotherapy or immunotherapy",
                    "criterion": "concurrent chemotherapy or immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Hydroxyurea for blast count control is permitted before starting treatment and up to a maximum of 10 days after starting treatment on the study",
                    "criterion": "hydroxyurea use for blast count control",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "before starting treatment",
                                "up to a maximum of 10 days after starting treatment"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}